Archive for June, 2005

Pfizer: Viagra Not Linked to Blindness

“Following a review of its impotence drug Viagra, Pfizer Latest News about Pfizer, the world’s biggest drugmaker, has concluded that there is no apparent link between the medication and an increased risk of blindness.
“Nevertheless, the company said in a statement Monday that it would update the Viagra label to reflect reports of a serious eye […]

Thursday, June 30th, 2005

Leaked memo implicates Merck in Vioxx scandal

“New evidence has suggested that Merck & Co knew of the risks associated with the painkiller Vioxx before it was taken off the market. A leaked memo shows the company planned to reformulate the drug in 2000 to reduce its cardiovascular side effects.
“Merck & Co researchers are said to have become concerned over the safety […]

Wednesday, June 29th, 2005

Corgentech drug found to reduce inflammation in bowel disease

“California-based biotechnology firm Corgentech has received positive preclinical data from studies investigating its NF-kappaB Decoy drug candidate. The results show the drug to be effective at reducing disease activity in acute inflammatory bowel disease.
“The studies used rodent models of chronic Crohn’s disease and ulcerative colitis, `both also referred inflammatory bowel disease (IBD). The kappaB Decoy […]

Wednesday, June 29th, 2005

AstraZeneca’s migraine spray proves effective in adolescents

“British drug maker AstraZeneca has had promising results from a study trialing its nasal headache spray Zomig in adolescents. The data indicates the drug to be nearly 15% more effective than placebo at reducing headaches one hour after administration.
“Zomig (zolmitriptan) nasal spray 5mg achieved a 58.1% headache response rate in adolescents compared to a 43.3% […]

Monday, June 27th, 2005

Halozyme’s human enzyme proves safe in clinical trial

“Halozyme Therapeutics has received positive data from a clinical trial evaluating the safety of human hyaluronidase in healthy volunteers. Researchers found an absence of allergic reactions to the enzyme which produced less discomfort on administration than the control substance.
“The double-blinded clinical study compared recombinant human hyaluronidase (rHuPH20) to a saline control in 100 healthy human […]

Friday, June 24th, 2005

Glaxo To Help Develop AIDS Vaccine

“The global push to develop an AIDS vaccine was boosted by the first alliance between a major drug-maker and the non-profit sector to tackle the disease.
“Pharmaceuticals giant GlaxoSmithKline has signed a deal with the International AIDS Vaccine Initiative (IAVI) to research and develop a vaccine.
“Development will concentrate on a chimpanzee virus which has been engineered […]

Thursday, June 23rd, 2005

FDA endorses restrictions on Iressa

“AstraZeneca has agreed to limit access to its lung cancer drug Iressa after the FDA concluded that clinical testing had been unable to prove the treatment’s survival benefit.
“Based on the FDA’s assessment of currently data and the availability of other treatment options in the US that do prolong life, AstraZeneca said that it would revise […]

Wednesday, June 22nd, 2005

Panel Endorses Heart Drug for Black Patients

“Despite its racial overtone, U.S. health advisers have endorsed BiDil, a drug specifically targeted to treat heart failure in African-Americans.
“The action by a Food and Drug Administration advisory panel makes BiDil, made by NitroMed Inc. of Lexington, Mass., the first such medicine directed at a specific racial group, the Washington Post Latest News about Washington […]

Monday, June 20th, 2005

FDA approves Tygacil(tm), first-in-class antibiotic

“The U.S. Food and Drug Administration (FDA) today approved Tygacil(TM) (tigecycline), a novel I.V. antibiotic with a broad spectrum of antimicrobial activity, including activity against the drug-resistant bacteria methicillin-resistant Staphylococcus aureus (MRSA). TYGACIL is indicated for the treatment of complicated intra- abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults. Approval […]

Friday, June 17th, 2005

Biogen proves drug combo slows cancer

“Results from a phase II trial conducted by Biogen Idec demonstrated that galiximab may be used as an adjunct to Rituxan to produce a combination with the potential to prolong survival in follicular non-Hodgkin’s lymphoma.
“The data indicates that the combination treatment provides longer event-free survival (EFS) in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) […]

Friday, June 17th, 2005

problogger | blog design | digital camera reviews | digital photography school
american idol review | australian idol review | nz idol review | canadian idol review | NZ TV Guide | Shortland Street
| optimum internet | uav

Television Communities: New Zealand | Australia | Canada | UK

Beijing Olympic Games

American Idol Finalists: David Cook | David Archuleta | Syesha Mercado